The Efficacy of Short-term Administration of Revaprazan on Gastroesophageal Reflux Symptoms: Comparison with Half Dose Esomeprazole, a Pilot Study
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
;
: 23-26, 2012.
Artículo
en Coreano
| WPRIM
| ID: wpr-124166
ABSTRACT
BACKGROUND/AIMS:
Revaprazan, an acid pump antagonist, is a kind of gastric acid suppressant and is prescribed for the treatment of peptic ulcers and gastritis. However, the efficacy of revaprazan on gastroesophageal reflux symptoms has not been established. The aim of this study was to evaluate the short-term efficacy of revaprazan on gastroesophageal reflux symptoms. MATERIALS ANDMETHODS:
Patients who complained of gastroesophageal reflux symptoms without any specific diseases except gastritis on esophagogastroduodenoscopy were included in this study. Patients were randomized to receive revaprazan 200 mg or esomeprazole 20 mg for 2 weeks. Symptoms were assessed by using the frequency score questionnaire before and after treatment.RESULTS:
Fifteen patients received revaprazan and 19 patients received esomeprazole. The changes of the symptom frequency score before and after treatment were 7.0 in revaprazan group and 8.6 in esomeprazole group (P=0.778).CONCLUSIONS:
Revaprazan is not inferior to esomeprazole in therapeutic efficacy for gastroesophageal reflux symptoms and is a safe and useful therapeutic agent to reduce the frequency of gastroesophageal reflux symptoms.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Úlcera Péptica
/
Pirimidinonas
/
Reflujo Gastroesofágico
/
Proyectos Piloto
/
Encuestas y Cuestionarios
/
Endoscopía del Sistema Digestivo
/
Tetrahidroisoquinolinas
/
Esomeprazol
/
Ácido Gástrico
/
Gastritis
Tipo de estudio:
Ensayo Clínico Controlado
/
Estudio diagnóstico
Límite:
Humanos
Idioma:
Coreano
Revista:
The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Año:
2012
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS